We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a...
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -4.11 | -14.1724137931 | 29 | 31.13 | 23.976 | 19051 | 26.63195021 | CS |
4 | -4.11 | -14.1724137931 | 29 | 31.13 | 23.976 | 19051 | 26.63195021 | CS |
12 | -4.11 | -14.1724137931 | 29 | 31.13 | 23.976 | 19051 | 26.63195021 | CS |
26 | -4.11 | -14.1724137931 | 29 | 31.13 | 23.976 | 19051 | 26.63195021 | CS |
52 | -4.11 | -14.1724137931 | 29 | 31.13 | 23.976 | 19051 | 26.63195021 | CS |
156 | -4.11 | -14.1724137931 | 29 | 31.13 | 23.976 | 19051 | 26.63195021 | CS |
260 | 0 | 0 | 0 | 31 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions